Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2020-12-29 DOI:10.2217/hep-2020-0017

Pierre Nahon, Manon Allaire, Jean-Charles Nault, Valérie Paradis

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) developed in non-alcoholic fatty liver disease (NAFLD) individuals presents substantial clinical and biological characteristics, which remain to be elucidated. Its occurrence in noncirrhotic patients raises issues regarding surveillance strategies, which cannot be considered as cost-effective given the high prevalence of obesity and metabolic syndrome, and furthermore delineates specific oncogenic process that could be targeted in the setting of primary or secondary prevention. In this context, the identification of a genetic heterogeneity modulating HCC risk as well as specific biological pathways have been made possible through genome-wide association studies, development of animal models and in-depth analyses of human samples at the pathological and genomic levels. These advances must be confirmed and pursued to pave the way for personalized management of NAFLD-related HCC.

查看原文本刊更多论文

确定非酒精性脂肪肝发展为肝细胞癌的机制。

非酒精性脂肪肝（NAFLD）患者发生的肝细胞癌（HCC）具有重要的临床和生物学特征，这些特征仍有待阐明。由于肥胖和代谢综合征的发病率很高，因此在非肝硬化患者中发生 HCC 引起了有关监控策略的问题，而监控策略不能被视为具有成本效益，此外，它还描述了在一级或二级预防中可以针对的特定致癌过程。在此背景下，通过全基因组关联研究、动物模型的开发以及在病理和基因组水平上对人类样本的深入分析，确定了调节 HCC 风险的遗传异质性以及特定的生物通路。这些进展必须得到证实和继续推进，以便为非酒精性脂肪肝相关 HCC 的个性化管理铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.